Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs 985

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 985 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Pipeline programs

Page 4 of 21

  1. Guselkumab Dose 1

    Janssen Cilag International NV

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  2. I4V-MC-JAHU

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  3. I4V-MC-JAHX

    Eli Lilly Co.

    Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

  4. I6T-MC-AMAX

    Eli Lilly Co.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

  5. I6T-MC-AMAY

    Eli Lilly Co.

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  6. I6T-MC-AMBA

    Eli Lilly Co.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  7. I6T-MC-AMCD

    Eli Lilly Co.

    Obesity or Overweight, Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  8. I6T-MC-AMCE

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  9. IM011-054

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  10. IM011-055

    Bristol-Myers Squibb Australia Pty Ltd

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  11. IM011-075

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate-to-Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  12. IM011-1071

    Bristol-Myers Squibb Australia Pty Ltd

    Juvenile Psoriatic Arthritis (JPsA)

    phase 3 small molecule active

    1 trial

  13. IM011-1128

    Bristol-Myers Squibb Australia Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  14. IM047-001

    Bristol-Myers Squibb Australia Pty Ltd

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  15. IM047-023

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  16. IM101-863

    Bristol-Myers Squibb Australia Pty Ltd

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  17. IRIS, D3466C00001

    AstraZeneca AB

    Active Proliferative Lupus Nephritis

    phase 3 small molecule active

    1 trial

  18. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  19. IV Tulisokibart

    Merck KGaA, Darmstadt, Germany

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  20. Icotrokinra

    Janssen Cilag International NV

    Crohn Disease

    phase 3 small molecule active

    1 trial

  21. Icotrokinra, JNJ-77242113-AAC Placebo tablet

    Janssen-Cilag International N.V.

    Moderately to Severely Active Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  22. Infliximab + methotrexate (IFX + MTX)

    Universal Integrated

    Arthritis, Psoriatic

    phase 3 small molecule completed

    1 trial

  23. Infliximab Increased Frequency

    Universal Integrated

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  24. Intravenous Immunoglobulin

    Option Therapeutics

    Autoimmune Epilepsy

    phase 3 small molecule terminated

    1 trial

  25. J2A-MC-GZPT

    Eli Lilly Co.

    Osteoarthritis

    phase 3 small molecule active

    1 trial

  26. JNJ-77242113

    Janssen Cilag International NV

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  27. JNJ-77242113-AAC Placebo tablet, JNJ-77242113

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  28. KHK4827

    KYOWA KIRIN AUSTRALIA PTY LTD

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule completed

    1 trial

  29. KYV-101

    Kyverna Therapeutics

    Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, Stiff Person Syndrome

    phase 3 small molecule active

    1 trial

  30. KYV101-006

    Kyverna Therapeutics

    Generalized myasthenia gravis

    phase 3 small molecule active

    1 trial

  31. LY2127399

    Eli Lilly and Company

    Systemic Lupus Erythematosus

    phase 3 small molecule completed

    1 trial

  32. LY2127399

    Eli Lilly and Company

    Rheumatoid Arthritis

    phase 3 small molecule terminated

    1 trial

  33. Lansoprazole and naproxen and aspirin

    Takeda

    Osteoarthritis

    phase 3 small molecule completed

    1 trial

  34. Leflunomide Mylan for polymyalgia rheumatica

    Disc Medicine

    polymyalgia rheumatica

    phase 3 small molecule active

    1 trial

  35. M10-870

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  36. M1095-PSA-301

    MoonLake Immunotherapeutics

    Psoriatic arthritis

    phase 3 small molecule active

    1 trial

  37. M1095-PSA-302

    MoonLake Immunotherapeutics

    psoriatic arthritis

    phase 3 small molecule active

    1 trial

  38. M14-533

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  39. M14-671

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease (CD)

    phase 3 small molecule active

    1 trial

  40. M14-682

    AbbVie Deutschland GmbH & Co. KG

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  41. M15-998

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  42. M16-000

    AbbVie Deutschland GmbH & Co. KG

    Crohn's Disease

    phase 3 small molecule active

    1 trial

  43. M16-011

    AbbVie Deutschland GmbH & Co. KG

    Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  44. M16-066

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  45. M16-194

    AbbVie Deutschland GmbH & Co. KG

    Crohn's disease

    phase 3 small molecule active

    1 trial

  46. M19-751

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  47. M23-732

    AbbVie Deutschland GmbH & Co. KG

    Juvenile Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  48. M25-540

    AbbVie Deutschland GmbH & Co. KG

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

985 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.